Par Drugs and Chemicals Limited (NSE:PAR)
India
· Delayed Price · Currency is INR 91.45
+1.28 (1.42%)
Mar 10, 2026, 12:53 PM IST
Par Drugs and Chemicals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,064 | 1,010 | 956.4 | 957.49 | 750.74 | 607.51 | Upgrade
|
| Revenue | 1,064 | 1,010 | 956.4 | 957.49 | 750.74 | 607.51 | Upgrade
|
| Revenue Growth (YoY) | 4.84% | 5.58% | -0.11% | 27.54% | 23.58% | 8.78% | Upgrade
|
| Cost of Revenue | 452.87 | 391.87 | 346.53 | 409.83 | 293.18 | 224.99 | Upgrade
|
| Gross Profit | 610.87 | 617.86 | 609.88 | 547.65 | 457.57 | 382.53 | Upgrade
|
| Selling, General & Admin | 60.95 | 58.52 | 54.99 | 48.88 | 41.01 | 39.78 | Upgrade
|
| Other Operating Expenses | 368.66 | 364.24 | 326.71 | 316.7 | 254.01 | 182.61 | Upgrade
|
| Operating Expenses | 466.56 | 459.23 | 416.06 | 397.91 | 327.83 | 250.59 | Upgrade
|
| Operating Income | 144.31 | 158.64 | 193.81 | 149.74 | 129.74 | 131.94 | Upgrade
|
| Interest Expense | -0.23 | - | - | -0.02 | -3.77 | -6.03 | Upgrade
|
| Interest & Investment Income | 10.81 | 10.81 | 2.32 | 0.72 | 1.84 | 1.32 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.99 | -0.82 | -1.07 | -1.31 | -0.78 | 0.17 | Upgrade
|
| EBT Excluding Unusual Items | 176.88 | 168.62 | 195.07 | 149.13 | 127.03 | 127.39 | Upgrade
|
| Gain (Loss) on Sale of Investments | 10.61 | 10.61 | 0.02 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.08 | 1.43 | - | 0 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 19.86 | Upgrade
|
| Pretax Income | 187.49 | 179.23 | 195.17 | 150.79 | 127.03 | 147.26 | Upgrade
|
| Income Tax Expense | 48.43 | 45.65 | 50.16 | 37.45 | 34.9 | 31.15 | Upgrade
|
| Net Income | 139.06 | 133.58 | 145.01 | 113.34 | 92.13 | 116.11 | Upgrade
|
| Net Income to Common | 139.06 | 133.58 | 145.01 | 113.34 | 92.13 | 116.11 | Upgrade
|
| Net Income Growth | -9.86% | -7.88% | 27.94% | 23.02% | -20.65% | 143.68% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | -0.05% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 11.31 | 10.86 | 11.78 | 9.21 | 7.49 | 9.44 | Upgrade
|
| EPS (Diluted) | 11.31 | 10.86 | 11.78 | 9.21 | 7.49 | 9.44 | Upgrade
|
| EPS Growth | -9.77% | -7.84% | 27.90% | 23.00% | -20.64% | 143.64% | Upgrade
|
| Free Cash Flow | - | 149.34 | 141.69 | 57.43 | 44.13 | 70.36 | Upgrade
|
| Free Cash Flow Per Share | - | 12.14 | 11.52 | 4.67 | 3.59 | 5.72 | Upgrade
|
| Dividend Per Share | - | - | - | - | 1.250 | - | Upgrade
|
| Gross Margin | 57.43% | 61.19% | 63.77% | 57.20% | 60.95% | 62.97% | Upgrade
|
| Operating Margin | 13.57% | 15.71% | 20.27% | 15.64% | 17.28% | 21.72% | Upgrade
|
| Profit Margin | 13.07% | 13.23% | 15.16% | 11.84% | 12.27% | 19.11% | Upgrade
|
| Free Cash Flow Margin | - | 14.79% | 14.81% | 6.00% | 5.88% | 11.58% | Upgrade
|
| EBITDA | 182.35 | 195.1 | 228.17 | 182.07 | 162.55 | 160.13 | Upgrade
|
| EBITDA Margin | 17.14% | 19.32% | 23.86% | 19.02% | 21.65% | 26.36% | Upgrade
|
| D&A For EBITDA | 38.04 | 36.47 | 34.36 | 32.33 | 32.81 | 28.19 | Upgrade
|
| EBIT | 144.31 | 158.64 | 193.81 | 149.74 | 129.74 | 131.94 | Upgrade
|
| EBIT Margin | 13.57% | 15.71% | 20.27% | 15.64% | 17.28% | 21.72% | Upgrade
|
| Effective Tax Rate | 25.83% | 25.47% | 25.70% | 24.84% | 27.47% | 21.15% | Upgrade
|
| Revenue as Reported | 1,108 | 1,031 | 958.83 | 959.87 | 752.58 | 609.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.